Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

NCT07180056 · clinicaltrials.gov ↗

RECRUITING

Status

229

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: CDK4/6 inhibitor

Sponsor

Wenjin Yin